Managing Castration-Resistant Prostate Cancer:
Understanding the Therapeutic Landscape

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie, Inc.,
Astellas Scientific & Medical Affairs, Inc and Medivation,
and Sanofi Genzyme

Prostate cancer is the second leading cause of cancer deaths among American men, which is typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. The treatment of CRPC has dramatically changed over the past decade and despite recent advances, the prognosis for patients still need improvement, with a significant impact on patients’ quality of life, resulting predominantly from skeletal metastases. Patients with all stages of CRPC have many treatment options available starting with frontline to second-line therapy and to immunotherapy and chemotherapy. For many years, cytotoxic chemotherapy with docetaxel was the common form of treatment for in patients with symptomatic or rapidly progressing disease, but recent emerging therapies are demonstrating improved survival with a variety of advanced therapeutic agents. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease.

Upon Completion of this activity, participants will be able to:

  • Assess the safety and efficacy for available therapies in the treatment of CRPC

  • Discuss the updated guidelines and recent clinical data on diagnostic options in advanced prostate cancer

  • Explore clinical evidence and data on current and novel strategies for CRPC treatment, including systematic and biologic therapies

  • Discuss the importance of patient education which includes adherence, side effects and active participation in decision making

  • Analyze the optimal sequencing of therapies for treatment of CRPC

Faculty: Michael Hurwitz, MD, PhD
Assistant Professor of Medicine
Section of Medical Oncology
Yale Comprehensive Cancer Center


Dr. Hurwitz serves as a consultant to Nektar Therapeutics. His spouse/partner receives salary or contractual payment from Pfizer. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AbbVie, Inc.,
Astellas Scientific & Medical Affairs, Inc and Medivation,
and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue